Literature DB >> 2459412

Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies.

L J Anderson1, P Bingham, J C Hierholzer.   

Abstract

We identified several types of neutralization effected by F and G protein monoclonal antibodies (MAbs) reacted individually or as mixtures against respiratory syncytial virus (RSV). Neutralizing activity was identified by a microneutralization test in which virus replication was determined by enzyme immunoassay. Complete neutralization was seen only with MAbs against the F protein. Strain-specific neutralization, complete neutralization against some strains of RSV, and no neutralization against other strains were seen with an additional MAb against the F protein. Partial neutralization, virus replication significantly reduced but still present, and no neutralization were seen with MAbs against both the F and G proteins. Enhanced neutralization, enhanced efficacy of neutralization, or increased neutralizing titer with a mixture of two MAbs over that for the individual MAbs was seen with all MAbs against the F protein and all but three MAbs against the G protein. Most (10 of 13) of the MAbs that exhibited neutralizing activity reacted with some but not all strains of RSV in an enzyme immunoassay. The epitopes corresponding to these 10 MAbs probably contribute to the strain-specific component of the neutralizing antibody response to RSV. Our results suggest that interpretation of RSV neutralization with MAbs is complex and that studies of such neutralization should include mixtures of MAbs and multiple RSV strains.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459412      PMCID: PMC253856     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Antigenic differences between two strains of respiratory syncytial virus.

Authors:  H V COATES; L KENDRICK; R M CHANOCK
Journal:  Proc Soc Exp Biol Med       Date:  1963-04

2.  Serological studies with respiratory syncytial virus.

Authors:  J E Doggett; D Taylor-Robinson
Journal:  Arch Gesamte Virusforsch       Date:  1965

3.  Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity.

Authors:  W A Volk; R M Synder; D C Benjamin; R R Wagner
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

4.  Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein.

Authors:  E E Walsh; J Hruska
Journal:  J Virol       Date:  1983-07       Impact factor: 5.103

5.  Classification of hybridomas to respiratory syncytial virus glycoproteins.

Authors:  B F Fernie; P J Cote; J L Gerin
Journal:  Proc Soc Exp Biol Med       Date:  1982-12

6.  Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections.

Authors:  M P Cranage; P S Gardner
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

7.  Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus.

Authors:  C L Lamprecht; H E Krause; M A Mufson
Journal:  J Infect Dis       Date:  1976-09       Impact factor: 5.226

8.  Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

Authors:  G A Prince; V G Hemming; R L Horswood; R M Chanock
Journal:  Virus Res       Date:  1985-10       Impact factor: 3.303

9.  Maternal antibody and respiratory syncytial virus infection in infancy.

Authors:  M M Ogilvie; A S Vathenen; M Radford; J Codd; S Key
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

10.  Viral epitopes and monoclonal antibodies: isolation of blocking antibodies that inhibit virus neutralization.

Authors:  R J Massey; G Schochetman
Journal:  Science       Date:  1981-07-24       Impact factor: 47.728

View more
  72 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Premature stop codons in the G glycoprotein of human respiratory syncytial viruses resistant to neutralization by monoclonal antibodies.

Authors:  P Rueda; T Delgado; A Portela; J A Melero; B García-Barreno
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

3.  Antigenic characterization of respiratory syncytial virus group A and B isolates in Rio de Janeiro, Brazil.

Authors:  M M Siqueira; J P Nascimento; L J Anderson
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

4.  Induction of a neutralizing immune response to human respiratory syncytial virus with anti-idiotypic antibodies.

Authors:  C Palomo; J P Albar; B García-Barreno; J A Melero
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.

Authors:  A Leemans; M De Schryver; W Van der Gucht; A Heykers; I Pintelon; A L Hotard; M L Moore; J A Melero; J S McLellan; B S Graham; L Broadbent; U F Power; G Caljon; P Cos; L Maes; P Delputte
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

Review 6.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution?

Authors:  Alfonsina Trento; Leyda Ábrego; Rosa Rodriguez-Fernandez; Maria Isabel González-Sánchez; Felipe González-Martínez; Adriana Delfraro; Juan M Pascale; Juan Arbiza; José A Melero
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

Review 8.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

Review 9.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

10.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.